The demand for babesiosis treatment in USA is projected to grow from USD 0.5 billion in 2025 to USD 0.8 billion by 2035, at a CAGR of 4.8%. Generic will dominate with a 61.0% market share, while oral will lead the route of administration segment with a 64.0% share.